Optimizing denileukin diftitox (Ontak®) therapy

M Duvic

doi:10.4081/hmr.v2i13.491

Abstracts

10 June 2009

Vol. 2 No. 13 (2006)

https://doi.org/10.4081/hmr.v2i13.491

Optimizing denileukin diftitox (Ontak®) therapy

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

195

Views

759

Downloads

Authors

M Duvic

support@pagepress.org

Denileukin diftitox (Ontak®) is a genetically engineered recombinant fusion protein composed of the full length interleukin 2 and the catalytic domain of diphtheria toxin. As such, Ontak or formerly DAB389IL2 is the first targeted therapy of the fusion toxin class to be approved. This therapy has broad applicability for targeting any ligand receptor that internalizes after binding. Ontak was first introduced in 1992, and tested for safety and activity in autoimmune disease (rheumatoid arthritis, psoriasis), type I diabetes, HIV, and hematologic malignancies (Strom TB 1993).